{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:49:02Z","timestamp":1783997342750,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006605","name":"Oryzon Genomics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006605","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EUROSTARS-2\/CDTI, Spanish Ministry of Science, Innovation and Universities.","award":["CIIP-20152001\/E9683"],"award-info":[{"award-number":["CIIP-20152001\/E9683"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40263-021-00797-x","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T11:03:47Z","timestamp":1616497427000},"page":"331-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat"],"prefix":"10.1007","volume":"35","author":[{"given":"Rosa Mar\u00eda","family":"Antonijoan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Ferrero-Cafiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"Coimbra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Puntes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Mart\u00ednez-Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Ar\u00e9valo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mascar\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Molinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Buesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5104-6867","authenticated-orcid":false,"given":"Tamara","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"issue":"5","key":"797_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1177\/1073858418780971","volume":"24","author":"JD Barter","year":"2018","unstructured":"Barter JD, Foster TC. Aging in the brain: new roles of epigenetics in cognitive decline. Neuroscientist. 2018;24(5):516\u201325.","journal-title":"Neuroscientist"},{"key":"797_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3389\/fnins.2018.00649","volume":"12","author":"IC Wood","year":"2018","unstructured":"Wood IC. The contribution and therapeutic potential of epigenetic modifications in Alzheime\u2019s disease. Front Neurosci. 2018;12:649.","journal-title":"Front Neurosci."},{"issue":"1","key":"797_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13072-018-0251-8","volume":"12","author":"BE Collins","year":"2019","unstructured":"Collins BE, Greer CB, Coleman BC. Histone H3 lysine K4 methylation and its role in learning and memory. Epigenet Chromatin. 2019;12(1):7.","journal-title":"Epigenet Chromatin"},{"issue":"3","key":"797_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/15592294.2019.1583032","volume":"14","author":"CR Lewis","year":"2019","unstructured":"Lewis CR, Candace R, Lewis CR, Henderson-Smith A, Reagan S, Breitenstein RS, et al. Dopaminergic gene methylation is associated with cognitive performance in a childhood monozygotic twin study. Epigenetics. 2019;14(3):310\u201323.","journal-title":"Epigenetics"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13148-017-0365-z","volume":"9","author":"R Delgado-Morales","year":"2017","unstructured":"Delgado-Morales R, Ag\u00eds-Balboa RC, Esteller M. Epigenetic mechanisms during ageing and neurogenesis as novel therapeutic avenues in human brain disorders. Clin Epigenet. 2017;9:67.","journal-title":"Clin Epigenet"},{"issue":"4","key":"797_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2217\/epi.15.9","volume":"7","author":"T Maes","year":"2015","unstructured":"Maes T, Mascar\u00f3 C, Ortega A, Lunardi S, Ciceri F, Somervaille TCP, et al. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Epigenomics. 2015;7(4):609\u201326.","journal-title":"Epigenomics"},{"issue":"8","key":"797_CR7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41386-018-0300-9","volume":"44","author":"S Matsuda","year":"2019","unstructured":"Matsuda S, Baba R, Oki H, Morimoto S, Toyofuku M, Igaki S, et al. T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice. Neuropsychopharmacology. 2019;44(8):1505\u201312.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"797_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.neuron.2019.09.014","volume":"104","author":"J Mukai","year":"2019","unstructured":"Mukai J, Cannav\u00f2 E, Crabtree GW, Sun Z, Diamantopoulou A, Thakur P, et al. Recapitulation and reversal of schizophrenia-related phenotypes in Setd1a-deficient mice. Neuron. 2019;104(3):471-87.e12.","journal-title":"Neuron"},{"issue":"7","key":"797_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941\u201353.","journal-title":"Cell"},{"issue":"5","key":"797_CR10","doi-asserted-by":"publisher","first-page":"e0233468","DOI":"10.1371\/journal.pone.0233468","volume":"15","author":"T Maes","year":"2020","unstructured":"Maes T, Mascar\u00f3 C, Rotllant D, Lufino MMP, Estiarte A, Guibourt N, et al. Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. PLoS ONE. 2020;15(5):e0233468.","journal-title":"PLoS ONE"},{"key":"797_CR11","unstructured":"Maes T, Cavalcanti F, Gonz\u00e1lez-Rey E, Delgado M, Mascar\u00f3 C, Lufino MMP, et al. Characterization of the efficacy of ORY-2001, a novel epigenetic drug for the treatment of multiple sclerosis, during the effector phase of the EAE model [Abstract]. ECTRIMS Online Library. Maes T. 10\/26\/17; 200311; P656."},{"issue":"4","key":"797_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.molcel.2007.06.039","volume":"27","author":"S Saleque","year":"2007","unstructured":"Saleque S, Kim J, Rooke HM. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell. 2007;27(4):562\u201372.","journal-title":"Mol Cell."},{"issue":"9","key":"797_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2012.157","volume":"26","author":"A Spr\u00fcssel","year":"2012","unstructured":"Spr\u00fcssel A, Schulte JH, Weber S, Necke M, H\u00e4ndschke K, Thor T, et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia. 2012;26(9):2039\u201351.","journal-title":"Leukemia"},{"key":"797_CR14","unstructured":"EMA. European Medicines Agency. Guideline on requirements for first-in-man clinical trials for potential High-Risk medicinal products. 2007. EMEA\/CHMP\/SWP\/28367\/2007Corr."},{"key":"797_CR15","unstructured":"FDA. U.S. Food and Drug Administration: Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005."},{"issue":"20","key":"797_CR16","doi-asserted-by":"publisher","first-page":"8311","DOI":"10.1074\/jbc.RA118.006980","volume":"294","author":"C Mascar\u00f3","year":"2019","unstructured":"Mascar\u00f3 C, Ortega A, Carceller E, Ruiz Rodriguez R, Ciceri F, Lunardi S, et al. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable in vivo pharmacokinetics and pharmacodynamics studies of KDM1A inhibitors. J Biol Chem. 2019;294(20):8311\u201322.","journal-title":"J Biol Chem"},{"key":"797_CR17","doi-asserted-by":"publisher","DOI":"10.3791\/59390","author":"C Mascar\u00f3","year":"2019","unstructured":"Mascar\u00f3 C, Ruiz Rodriguez R, Maes T. Direct measurement of KDM1A target engagement using chemoprobe-based immunoassays. J Vis Exp. 2019. https:\/\/doi.org\/10.3791\/59390.","journal-title":"J Vis Exp"},{"issue":"36","key":"797_CR18","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.19.03250","volume":"38","author":"O Salamero","year":"2020","unstructured":"Salamero O, Montesinos P, Willekens C, P\u00e9rez-Sim\u00f3n JA, Pigneux A, R\u00e9cher C, et al. First-in-human phase I study of Iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2020;38(36):4260\u201373.","journal-title":"J Clin Oncol"},{"key":"797_CR19","doi-asserted-by":"crossref","unstructured":"Pettit K, Gerds AT, Tacoub A, Watts JM, Tartaczuch M, Bradley TJ, et al. A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the treatment of myelofibrosis [Abstract]. Blood. 2019;134(Supplement_1):556.","DOI":"10.1182\/blood-2019-123244"},{"key":"797_CR20","doi-asserted-by":"crossref","unstructured":"Hollebecque A, de Bono JS, Plummer R, Isambert N, Martin-Romano P, Baudin E, et al. Phase I study of CC-90011 in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin lymphoma (R\/R NHL) [Abstract]. 2018. Ann Oncol. 2018;29(suppl_8):viii649\u2013viii669.","DOI":"10.1093\/annonc\/mdy303.002"},{"issue":"13 Suppl","key":"797_CR21","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/1538-7445.AM2018-1888","volume":"78","author":"A Chadderton","year":"2018","unstructured":"Chadderton A, Ye M, Diamond M, Roman V, Weber M, He C, et al. The FAD-directed LSD1 specific inhibitor, INCB059872, is a promising epigenetic agent for AML therapy by inducing differentiation of leukemic stem\/progenitor cells [Abstract]. Cancer Res. 2018;78(13 Suppl):1888.","journal-title":"Cancer Res"},{"key":"797_CR22","unstructured":"Ramos-Quiroga JA, Bullock R, Ferrer M, Fadeuilhe C, Guti\u00e9rrez S, Richarte V, et al. PS01.48. Vafidemstat: an epigenetic drug with emerging therapeutic potential, composite data from three psychiatric disorders from the REIMAGINE trial [Abstract]. 2019 CINP Intl. Meeting, Athens, 3\u20135 October 2019. http:\/\/bit.ly\/2Dxmtj0. http:\/\/bit.ly\/2DzW4RL. Accessed 22 Feb 2021."},{"key":"797_CR23","doi-asserted-by":"publisher","unstructured":"Bullock R, Ferrer M, Gutierrez S, Richarte V, Gisbert L, Lara B, et al. EPP0681. Vafidemstat reduces aggressiveness in three different psychiatric disorders. Final data from the reimagine trial. [Abstract]. European Psychiatry, Volume 63, Special Issue S1: Abstracts of the 28th European Congress of Psychiatry, 2020, S170\u2013S171. https:\/\/doi.org\/10.1192\/j.eurpsy.2020.5.","DOI":"10.1192\/j.eurpsy.2020.5"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-021-00797-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T06:17:57Z","timestamp":1671689877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-021-00797-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00797-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"12 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: RMA, TM, CMo, CB. Formal analysis: MIA, RMA, JMF-C, JM-C, JC. Funding acquisition: CB, TM. Investigation: RMA, JMF-C, JMC, JC, CMa, MIA. Methodology: TM. Project Administration: CMo, RMA. Resources: RMA, JMF-C, JM-C, JC. Supervision: RMA, CMo. Visualization: MIA. Original draft preparation: RMA, TM, MIA. All authors contributed to the review and editing of this article. All authors approved the content of the manuscript and take responsibility for the content of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The open access fee was paid by Oryzon Genomics, S.A. This study was funded by Oryzon Genomics, S.A. (the sponsor), and grant CIIP-20152001\/E9683, EUROSTARS-2\/CDTI, Spanish Ministry of Science, Innovation and Universities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RMA has received personal fees from Centre d\u2019Investigaci\u00f3 del Medicament, Institut de Recerca de l\u2019Hospital de la Santa Creu\u00a9 Sant Pau (IIB-Sant Pau) and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. JMF-C, JC, MP, and JM-C have received personal fees from Centre d\u2019Investigaci\u00f3 del Medicament, Institut de Recerca de l\u2019Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain. MIA, CMa, CMo, CB, and TM have received personal fees from Oryzon Genomics, during the conduct of the study. In addition, CMa is listed as inventor on patent application WO2017\/158136 (pending), assigned to Oryzon Genomics; CMo owns company shares on the stock exchange (Oryzon Genomics); and CB reports patent WO2012\/013728 (issued in multiple countries), assigned to Oryzon Genomics. CB is executive director and shareholder of Oryzon Genomics. TM has received other compensation from the Alzheimer\u2019s Drug Discovery Foundation, outside the submitted work; is listed as inventor in WO2017\/158136 (pending), WO2017\/212061 (issued in multiple countries), and WO2019\/025588 (pending) and further reports patent WO2012\/013728 (issued in multiple countries), all assigned to Oryzon Genomics; is executive director and shareholder of Oryzon Genomics; and is a member of the Scientific Review Board of the Alzheimer\u2019s Drug Discovery Foundation, for which no compensation is received.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was registered under EUDRACT No. 2015-003721-33 and carried out in accordance with the protocol CL01-ORY-2001 and good clinical practices (Declaration of Helsinki, guideline ICH CPMP\/ICH\/135\/95, European Directive 2001\/20\/EC, and Spanish RD 561\/1993 and RD 223\/2004). The study protocol and informed consent forms were approved by the Spanish Agency for Medicines and Health Products and the institutional review board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all candidate subjects participating in this study before any clinical procedures were undertaken.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The written informed consent allows publication of the data included in this manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Materials can be obtained through a material transfer agreement upon reasonable request. The KDM1A Target Engagement Method validation protocol and report are available upon request. Access to the full trial protocol and clinical trial data can be obtained through a data-sharing agreement upon reasonable request and in compliance with applicable laws. Contact the corresponding author or email info@oryzon.com.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}